{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:17:40Z","timestamp":1789823860283,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","drugandalcoholdependence.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.drugalcdep.2016.03.017","type":"journal-article","created":{"date-parts":[[2016,3,28]],"date-time":"2016-03-28T16:00:55Z","timestamp":1459180855000},"page":"227-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Factors associated with non-adherence and misuse of opioid maintenance treatment medications and intoxicating drugs among Finnish maintenance treatment patients"],"prefix":"10.1016","volume":"162","author":[{"given":"Essiina","family":"Launonen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isla","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Kotovirta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannu","family":"Alho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaarlo","family":"Simojoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0005","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.drugalcdep.2014.12.002","article-title":"Illicit use of opioid substitution drugs: prevalence user characteristics, and the association with non-fatal overdoses","volume":"147","author":"Bretteville-Jensen","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0376-8716(03)00189-3","article-title":"Evaluation of buprenorphine maintenance treatment in a French cohort of HIV-infected injecting drug users","volume":"72","author":"Carrieri","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0015","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.drugalcdep.2013.05.028","article-title":"Effectiveness of prize-based contingency management in a methadone maintenance program in China","volume":"133","author":"Chen","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0020","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1360-0443.2009.02843.x","article-title":"Abuse liability of intravenous buprenorphine\/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers","volume":"105","author":"Comer","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0025","first-page":"23","article-title":"Quality of care provided to patients receiving opioid maintenance treatment in Europe: results from the EQUATOR analysis","volume":"14","author":"Dale-Perera","year":"2012","journal-title":"Heroin Addic. Relat. Clin. Probl."},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0030","series-title":"A Global Review Of Availability, Extra-Medical Use, Injection And The Association With HIV","article-title":"Benefits and risks of pharmaceutical opioids: essential treatment and diverted medication","author":"Degenhardt","year":"2008"},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5694\/j.1326-5377.2009.tb02729.x","article-title":"Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation","volume":"191","author":"Degenhardt","year":"2009","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0040","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11606-006-0258-x","article-title":"Brief report: methadone treatment of injecting opioid users for prevention of HIV infection","volume":"21","author":"Gowing","year":"2006","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0045","first-page":"CD004145","article-title":"Oral substitution treatment of injecting opioid users for prevention of HIV infection","author":"Gowing","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0050","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1046\/j.1360-0443.2003.00500.x","article-title":"Illicit drug use and injection practices among drug users on methadone and buprenorphine maintenance treatment in France","volume":"98","author":"Guichard","year":"2003","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0055","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.drugpo.2010.10.004","article-title":"The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia","volume":"22","author":"Horyniak","year":"2011","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0060","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00414-014-1017-x","article-title":"Intravenous methadone application as a serious risk factor for an overdose death: methadone-related fatalities in Hamburg from 2007 to 2012","volume":"128","author":"Iwersen-Bergmann","year":"2014","journal-title":"Int. J. Legal Med."},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0065","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1360-0443.2004.00958.x","article-title":"Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue?","volume":"100","author":"Jenkinson","year":"2005","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0070","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.drugalcdep.2011.04.002","article-title":"Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion: injection and adherence with supervised dosing","volume":"118","author":"Larance","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0075","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1465-3362.2010.00283.x","article-title":"Definitions related to the use of pharmaceutical opioids: extramedical use diversion, non-adherence and aberrant medication-related behaviours","volume":"30","author":"Larance","year":"2011","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0080","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.drugalcdep.2013.12.005","article-title":"The diversion and injection of a buprenorphine-naloxone soluble film formulation","volume":"136","author":"Larance","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0085","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.drugpo.2015.03.007","article-title":"Diversion of opioid maintenance treatment medications and predictors for diversion among Finnish maintenance treatment patients","volume":"26","author":"Launonen","year":"2015","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0090","article-title":"Decree of the ministry of social affairs and health on the detoxification and substitution treatment of opioid addicts with certain medicinal products","volume":"33","author":"MSAH,","year":"2008","journal-title":"Helsinki"},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0095","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1360-0443.1998.9345157.x","article-title":"The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis","volume":"93","author":"Marsch","year":"1998","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0100","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1360-0443.2003.00335.x","article-title":"Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients","volume":"98","author":"Mattick","year":"2003","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0105","first-page":"CD002209","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0110","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"Suppl. 1","key":"10.1016\/j.drugalcdep.2016.03.017_bib0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/11536020-000000000-00000","article-title":"Intravenous misuse of buprenorphine: characteristics and extent among patients undergoing drug maintenance therapy","volume":"30","author":"Moratti","year":"2010","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0120","first-page":"498","article-title":"The prevalence of amphetamine and opioid abuse in Finland in 2012","volume":"5","author":"Ollgren","year":"2014","journal-title":"Yhteiskuntapolitiikka"},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0125","first-page":"481","article-title":"Detoxification and substitution in the treatment of opioid addicts in Finalnd in 2011: is treatment becoming more varied?","volume":"69","author":"Partanen","year":"2014","journal-title":"Finn. Med. J."},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.drugalcdep.2008.03.025","article-title":"Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management","volume":"97","author":"Roux","year":"2008","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0135","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.addbeh.2008.07.018","article-title":"Buprenorphine sniffing as a response to inadequate care in substituted patients: results from the Subazur survey in south-eastern France","volume":"33","author":"Roux","year":"2008","journal-title":"Addict. Behav."},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0140","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1176\/appi.ajp.162.2.340","article-title":"Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence","volume":"162","author":"Schottenfeld","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jsat.2010.03.014","article-title":"Self-treatment: illicit buprenorphine use by opioid-dependent treatment seekers","volume":"39","author":"Schuman-Olivier","year":"2010","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0150","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0376-8716(02)00312-5","article-title":"Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France","volume":"69","author":"Vidal-Trecan","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0155","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.addbeh.2013.03.009","article-title":"Participation in opioid substitution treatment reduces the rate of criminal convictions: evidence from a community study","volume":"38","author":"Vorma","year":"2013","journal-title":"Addict. Behav"},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0160","author":"WHO","year":"1994","journal-title":"Lexicon of Alcohol and Drug Terms"},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0165","author":"WHO","year":"2009","journal-title":"Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence"},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0170","doi-asserted-by":"crossref","first-page":"e87931","DOI":"10.1371\/journal.pone.0087931","article-title":"Long-term effects of methadone maintenance treatment with different psychosocial intervention models","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0175","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3109\/10826080903080664","article-title":"Diversion and injection of methadone and buprenorphine among clients in public opioid treatment clinics in New South Wales","volume":"45","author":"Winstock","year":"2010","journal-title":"Aust. Subst. Use Misuse"},{"key":"10.1016\/j.drugalcdep.2016.03.017_bib0180","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.drugpo.2007.03.002","article-title":"Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales","volume":"19","author":"Winstock","year":"2008","journal-title":"Aust. Int. J. Drug Policy"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871616300047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871616300047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T21:36:28Z","timestamp":1600378588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871616300047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":36,"alternative-id":["S0376871616300047"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.03.017","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors associated with non-adherence and misuse of opioid maintenance treatment medications and intoxicating drugs among Finnish maintenance treatment patients","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}